According to a new report, published by KBV research, The Global Cardiac Marker Testing Market size is expected to reach $8.1 billion by 2028, rising at a market growth of 8.3% CAGR during the forecast period.
The Myocardial Infarction segment is generating highest revenue share in the Global Cardiac Marker Testing Market by Disease in 2021 thereby, achieving a market value of $3.1 billion by 2028. This is attributable to the increasing prevalence of myocardial worldwide. Myocardial infarction research is projected to generate lucrative opportunities due to the increased attention it has received.
The Point-of-Care Testing Facilities segment is showcasing a CAGR of 8.8% during (2022 - 2028). Increased use and adoption of extremely sensitive and user-friendly POC Troponin assays have led to meteoric expansion in the point-of-care testing market. There is a growing need for efficient, value-based healthcare services despite constrained financial resources, and POC testing is becoming increasingly important in this context. These tests are also the most preferred option for doctors to use in critical situations because they allow for a quicker diagnosis.
The Reagents & Kits segment is leading the Global Cardiac Marker Testing Market by Product in 2021 thereby, achieving a market value of $5.1 billion by 2028. Due to the high incidence of cardiovascular diseases and the growing elderly patient population around the world, a growing amount of cardiac biomarker tests are being performed, which is being blamed for the rise of the market for cardiac marker testing reagents & kits. The demand for quick detection of CVD has increased, leading to the widespread use of cardiac biomarker fast test kits.
The Creatine kinase-MB(CK-MB) segment has shown the growth rate of 8.8% during (2022 - 2028). Troponin has mainly taken the position of creatine kinase-MB. It may occasionally be utilized to aid in the early detection of a subsequent heart attack that happens soon after the first. When heart muscle cells are damaged, a specific version of the enzyme creatine kinase called CK-MB rises. It can be utilized as a follow-up test for an increased CK level and/or when a troponin test is not available.
The North America market dominated the Global Cardiac Marker Testing Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $3 billion by 2028.The Europe market is exhibiting a CAGR of 8.1% during (2022 - 2028). Additionally, The Asia Pacific market would showcase a CAGR of 9.1% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/cardiac-marker-testing-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of F. Hoffmann-La Roche Ltd., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG (Siemens AG), PerkinElmer, Inc., BioMérieux S.A., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., and DiaSorin S.p.A.
By Disease
By End User
By Product
By Biomarker Type
By Geography
Companies Profiled
Unique Offerings 
